This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percentage of Participants Who Experienced Any Adverse Events (AEs), AEs Grade 3 or 4, AEs Leading to Drug Interruptions or Discontinuations and Any Serious Adverse Events (SAEs)
Timeframe: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Percentage of Participants Who Died Due to Adverse Events, Disease Progression or Other Reasons
Timeframe: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Percentage of Participants Who Report a Shift in NCI CTCAE Grades to 3/4 in Hematology and Biochemistry Laboratory Parameters
Timeframe: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Exposure to Study Treatment: Duration on Treatment
Timeframe: Baseline to the data cut-off of 14 June 2017 (up to 6 years)
Exposure to Study Treatment - Dose Intensity
Timeframe: Baseline to the data cut-off of 14 June 2017 (up to 6 years)